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Aim To compare the early biochemical response and rate 
of adverse effects in patients who received prednisolone 
(PRED)/azathioprine (AZA) and those who received budes-
onide (BUD)/AZA as the first-line treatment for autoim-
mune hepatitis.
Methods The study involved 25 patients receiving PRED 
30 mg/day + AZA 50 mg/day and 25 patients receiving 
BUD 9 mg/day + AZA 50 mg/day from February 2015 to 
February 2018. Biochemical and hemogram data at base-
line and after 6 months of treatment, and adverse effects 
observed in the follow-up, were compared.
Results There was no difference between the groups in 
biochemical response (17 patients receiving PRED/AZA 
and 18 receiving BUD/AZA) and the rate of adverse effects 
(9 patients receiving PRED/AZA and 5 receiving BUD/AZA). 
The total number of adverse effects in the BUD/AZA group 
was lower (15 vs 7) and the treatment was discontinued 
in 2 (8%) patients in PRED/AZA group, while no treatment 
discontinuation was observed in BUD/AZA group.
Conclusions This study showed no differences in bio-
chemical response between the groups. Lower, although 
not significantly, rate of adverse effects and lower total 
number of adverse effects indicate that BUD/AZA may po-
tentially be used as the first-line treatment of choice, espe-
cially in patients with obesity, diabetes, resistant hyperten-
sion, glaucoma, or osteoporosis.
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AIH is an autoimmune liver disease that may lead to chron-
ic liver disease and cirrhosis in untreated patients. The dis-
ease is characterized by autoantibody positivity and ele-
vated levels of gamma globulins with necroinflammatory 
activity and signs of chronic hepatitis, and is often histo-
pathologically associated with interface hepatitis (1,2). Dis-
ease affects patients of all ages, predominantly women 
(women/men:4/1) (3). The diagnosis is based on diagnos-
tic criteria rather than on a specific laboratory test. AIH is 
classified according to serological test results into type 1 
and type 2 disease. Type 1 AIH is characterized by the pres-
ence of anti-nuclear antibodies (ANA) and/or anti-smooth 
muscle antibodies (anti-SMA). Type 2 disease is character-
ized by the presence of anti-liver kidney microsomal an-
tibodies type 1 (anti-LKM1) and/or anti-liver cytosol (anti-
LC1) positivity (1).
AIH is the first liver disease with a demonstrated effect of 
pharmacological treatment on survival. Response rates 
with steroid-based immunosuppressive therapies range 
from 75 to 90% (4). The American Association for the Study 
of Liver Diseases (AASLD) practice guidelines recommend 
the following treatment regimens as first-line therapies (4): 
the initial treatment with prednisolone (PRED) 60 mg/day 
or a combination of PRED 30 mg/day and azathioprine 
(AZA) 50 mg/day. PRED treatment may lead to a poor re-
sponse and steroid-related adverse effects. These adverse 
effects depend on the dose and time, occurring with the 
use of doses over 7.5-10 mg/day taken for more than a few 
months (4). The most common adverse effects are Cushin-
goid findings, while nearly half of the patients had their 
treatment discontinued due to cosmetic reasons and obe-
sity (5). Other adverse effects of steroid use are rare and 
include osteoporosis, diabetes, cataracts, psychosis, myo-
pathy, and hypertension (4). The majority of adverse effects 
occurs due to high-doses in the initial treatment regimens 
and are often reversible (6-8). Therefore, alternative treat-
ments have been used in the AIH, such as cyclosporine-A, 
tacrolimus, mycophenolate mofetil, budesonide (BUD), 
and ursodeoxycholic acid (9-11). Data on the efficacy and 
adverse effects of BUD in the first line treatment of AIH are 
limited. Therefore, we aimed to compare the early treat-
ment efficacy and adverse effects of patients receiving 
BUD and PRED in the first-line treatment of AIH.
This retrospective study compared patients receiving PRED/
AZA treatment and those receiving BUD/AZA treatment 
in terms of demographic data, liver biopsy activity scores, 
laboratory findings at baseline and after six months of 
treatment, and the rates of adverse effects.
Material and MethodS
Patient groups and study design
The study involved the last 25 patients treated with BUD/
AZA and the last 25 patients treated with PRED/AZA in the 
first line treatment of AIH at the Tepecik Training and Re-
search Hospital who were 18-year old or older and diag-
nosed with definite AIH according to the revised diagnos-
tic criteria (score >15) by the International Autoimmune 
Hepatitis Group (9) between February 2015 and February 
2018. The patients were treated with BUD/AZA because 
of comorbid diseases (obesity, hypertension, brittle dia-
betes, postmenopause, glaucoma). The included patients 
were required not to have received previous AIH treatment 
and had serum aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) levels two times higher than 
the reference levels. Exclusion criteria were viral infections 
including hepatitis A, B, C, D, and E; chronic liver diseases 
such as primary biliary cirrhosis, primary sclerosing cholan-
gitis, Wilson’s disease, or hemochromatosis; and liver cir-
rhosis and alcohol consumption.
In the PRED/AZA group, the treatment was started with a 
low dose of 30 mg/day PRED and 50 mg/day AZA. PRED 
was reduced to 10 mg/day according to weekly follow-
up at the end of first month, and this dose was continued 
as the maintenance therapy. In the BUD/AZA group, the 
treatment was started with 9 mg/day BUD and 50 mg/day 
AZA. BUD was continued with 9 mg/day as the mainte-
nance therapy. In both groups, AZA was increased to 1.5 
mg/kg/d in the first month with weekly follow-up.
Patients’ demographic data, autoimmune antibodies lev-
els, liver biopsy results (necroinflammatory activity and 
fibrosis scores) were compared between the groups at 
baseline. The levels of AST, ALT, alkaline phosphatase, gam-
ma-glutamyl transferase, total bilirubin, direct bilirubin, he-
moglobin, white blood cell, platelet, prothrombin time, 
and the international normalized ratio were compared be-
tween baseline and 6th month. ANA, SMA, anti-LKM1, and 
anti-LC1 were evaluated by indirect immunofluorescence 
on snap-frozen sections of the rat liver, kidney, and stom-
ach. Necroinflammation activity and fibrosis stage were as-
sessed by the Ishak modified histology activity index grad-
ing and staging system (12).
The groups were compared after six months of treatment 
with regards to the rates of complete biochemical re-
sponse (AST and ALT levels reaching the reference levels), 
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adverse effects (moon face, acne, hirsutism, striae, and buf-
falo hump; myopathy, etc), and treatment discontinuation. 
The study was approved by the Ethics Committee of Te-
pecik Training and Research Hospital (No: 2019/5-3).
Statistical analysis
The Kolmogorov-Smirnov test was used for normality test-
ing. Numerical variables are expressed as medians and 
interquartile ranges (IQR). χ2 test was used for the com-
parison of categorical values between the groups. Mann-
Whitney U test was used for the comparison of continuous 
independent variables, while Wilcoxon signed rank test 
was used for the comparison of dependent variables. The 
level of statistical significance was set at P < 0.05. Statisti-




The majority of study participants were women (40 out 
of 50), which is in accordance with the literature (1,13), 
and 94% of the patients had autoantibody positivity. The 
groups did not significantly differ in sex, mean age, au-
toantibody positivity, baseline necroinflammatory activity 
scores, and fibrosis scores (Table 1).
Biochemical laboratory findings
The groups at baseline and after six months of treatment 
did not significantly differ in laboratory findings other than 
the IgG levels (Table 2). IgG levels were not compared due 
to missing data in 30 patients.
Biochemical response and adverse effects
There was no significant differences between the groups 
in biochemical response rates (17 or 68% in PRED/AZA 
group vs 18 or 72% in BUD/AZA group, P = 0.231). There 
was also no significant difference in the rates of steroid-
related adverse effects (9 or 36% of patients in PRED/AZA 
group and 5 or 20% of patients in BUD/AZA group during 
the 6-month follow-up, P = 0.173) (Table 3). The number of 
adverse effects in the PRED/AZA and BUD/AZA groups was 
15 and 7, respectively. Two patients in the PRED/AZA group 
discontinued PRED due to severe myopathy and Cushin-
goid symptoms, and the treatment was continued as AZA 
monotherapy (Table 4). Three patients in both groups had 
the dose modified due to leukopenia. The treatment was 
not stopped or interrupted in any patient due to adverse 
effects related to AZA therapy.
diSCuSSion
This study showed no differences in biochemical response 
between the groups and a lower, although not significant-
ly, rate of adverse effects and lower total number of ad-
verse effects in BUD/AZA group.
The purpose of AIH treatment is to improve the clinical 
symptoms, transaminase and IgG levels, and histological 
activity. While the reduction of transaminase levels below 
two times the upper reference limit was previously consid-
ered as remission, it has been recently established that dis-
ease can progress in the presence of abnormal transami-
nase levels (14). The treatment is reduced to a minimum 
immunosuppressive dose for maintenance once remission 
is achieved.
BUD is a synthetic glucocorticoid with potent topical effects, 
undergoing first-pass elimination in a healthy liver (>90%) 
(15). It is not recommended for treatment in patients with 
liver cirrhosis and associated systemic shunts because the 
first-pass elimination does not occur in these individuals 
and systemic effects are increased (16,17). BUD, which has 
been used in AIH for 20 years, is associated with fewer ad-
verse effects and improves hepatic inflammatory activity 
(11,18). There are conflicting literature data regarding the 
taBle 1. age distribution, immunoglobulin G levels, necroinflammation, and fibrosis scores of patients receiving prednisolone/aza-
thioprine treatment and those receiving budesonide/azathioprine treatment
total Prednisolone/azathioprine Budesonide/azathioprine
Median (iQr) Median (iQr) Median (iQr) P*
Age (year)   47 (21)   48 (19.5)   43 (23.5) >0.999
Immunoglobulin G (mg/dL) 1975 (310) 1960 (235) 2010 (415)  0.356
Necroinflammation score (reference range: 0-18)    8 (5.3)    7 (5)    8 (6)  0.089
Fibrosis score (reference range: 0-6)    3 (3)    2 (3)    3 (2)  0.14
*Mann-Whitney u test.
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taBle 2. Comparison of laboratory findings of patients receiving prednisolone/azathioprine treatment and those receiving budes-
onide/azathioprine treatment at baseline and after six months of treatment*
total Prednisolone/azathioprine Budesonide/azathioprine
Median (iQr) Median (iQr) Median (iQr) P†
aSt (u/l)
baseline   99 (150.3)   89 (127.5)  123 (232.5) 0.322
6th month   31.5 (14.5)   32 (12)   31 (19.5) 0.877
P‡   <0.001   <0.001   <0.001
alt (u/l)
baseline  110 (128.8)  107 (101.5)  132 (212) 0.393
6th month   32 (18)   32 (10.5)   26 (24) 0.207
P‡   <0.001   <0.001   <0.001
total bilirubin (mg/dl)
baseline    0.8 (0.5)    0.7 (0.4)    1 (0.5) 0.385
6th month    0.7 (0.2)    0.7 (0.3)    0.7 (0.4) 0.724
P‡   <0.001    0.006    0.009
direct bilirubin (mg/dl)    
baseline    0.3 (0.5)    0.2 (0.5)      0.3 (0.5) 0.854
6th month    0.5 (0.3)    0.5 (0.2)    0.5 (0.4) 0.815
P‡    0.028    0.277    0.045
alP (u/l)
baseline  136 (95.8)  137 (101)  136 (157) 0.567
6th month   85.5 (52.3)   76 (52.5)   89 (47.5) 0.317
P‡   <0.001   <0.001   <0.001
GGt (u/l)
baseline   85.5 (111.3)   76 (77)   90 (188) 0.229
6th month   32 (32)   32 (52)   31 (31) 0.449
P‡   <0.001   <0.001   <0.001
albumin (g/dl)
baseline    4.1 (0.4)    4.2 (0.4)    4.1 (0.5) 0.063
6th month    4.2 (0.2)    4.2 (0.2)    4.2 (0.3) 0.142
P‡    0.011    0.461    0.003
WBC (/μl)
baseline 6450 (1,983) 6900 (2,155) 6300 (1,900) 0.351
6th month 7750 (2,425) 7800 (2,800) 7700 (2,600) 0.808
P‡    0.010    0.179    0.032
hemoglobin (g/dl)
baseline   12.5 (1.9)   12.3 (2.3)   12.7 (1.8) 0.308
6th month   12.7 (1.5)   12.3 (1.4)   13 (1.7) 0.190
P‡    0.135    0.331    0.229
Platelet ( × 103/μ)
baseline  259.5 (139.3)  263 (140.5)  255 (126) 0.900
6th month  290 (122)  295 (155)  289 (91.5) 0.594
P‡    0.012    0.027    0.253
Pt (s)
baseline   11.6 (2)   11.6 (2.2)   11.6 (2.2) 0.961
6th month   11 (1.5)   11.4 (1.5)   11 (1.7) 0.173
P‡   <0.001    0.062    0.001
inr
baseline    1.1 (0.2)    1.1 (0.2)    1 (0.1) 0.420
6th month    1 (0.2)    1 (0.1)    0.9 (0.2) 0.102
P‡    0.001    0.027    0.011
*aSt – aspartate aminotransferase; alt – alanine aminotransferase; alP – alkaline phosphatase; GGt – gamma-glutamyl transferase; WBC – white 
blood cell; Pt – prothrombin time; inr – international normalized ratio.
†Between groups (Mann-Whitney u test).
‡Within groups (Wilcoxon signed rank test).
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combination of BUD and AZA. A prospective, randomized 
trial of 203 naive or relapsed patients excluding cirrhotic 
patients showed that more patients had a complete bio-
chemical response in the BUD arm than in the PRED arm 
(19). A retrospective study of 60 patients showed that the 
biochemical response rate at the end of a six-month peri-
od in patients who were switched from PRED to BUD (ow-
ing to unresponsiveness or adverse effects) was 55% (20). 
Twenty-five percent of the patients were switched back to 
PRED treatment due to BUD-related adverse effects or an 
insufficient response (20). However, remission was main-
tained in all patients who had been already in remission at 
the time of medication switch. BUD treatment may be an 
alternative treatment option to standard PRED treatment 
in children (21); however, Czaja and Lindor (22) reported 
lower remission rates in patients receiving BUD. Danielsson 
and Prytz (18) reported that BUD treatment reduced liver 
inflammation only in patients with non-cirrhotic AIH. Fur-
thermore, Csepregi et al (23) reported that a complete re-
sponse was achieved in 83% patients receiving BUD at the 
6th month and cirrhosis was observed in 2 of 3 patients 
who could not respond to BUD treatment. In our study, the 
biochemical response rate at the 6th month in patients re-
ceiving BUD/AZA treatment was 72%, which is lower than 
in the study by Csepregi et al (23) but higher than in the 
study by Manns and Werner et al (19,20).
The most common problem in patients receiving long-
term steroid treatment are steroid-related adverse effects. 
Although their incidence was reduced with the introduc-
tion of immunosuppressive drugs such as AZA, they were 
reported in 44%-69% of patients receiving steroid therapy 
alone and in 10%-47% of patients receiving an AZA com-
bination regimen (4,6,16). In our study, steroid-related ad-
verse effects were reported in 9 (36%) patients in the PRED/
AZA group and in 5 (20%) patients in the BUD/AZA group. 
The total number of adverse effects in the PRED/AZA and 
BUD/AZA groups was 15 and 7, respectively. The treatment 
was discontinued in 2 (8%) patients receiving PRED/AZA 
therapy owing to severe myopathy and hirsutism, while 
no serious adverse effects leading to treatment discontin-
uation were observed in the patients receiving BUD/AZA 
treatment.
Although the duration of immunosuppressive therapy has 
not been definitely established, practice guidelines of both 
the AASLD and the European Association of Liver Research 
recommend that the treatment should be continued for at 
least 2 or 3 years, and that biochemical remission should be 
maintained for 2 years before discontinuation. The practice 
guidelines also recommend liver biopsy before treatment 
discontinuation since histological inflammatory activity 
may persist despite biochemical remission (4,17). It should 
be noted that 80% of the patients whose treatment was 
discontinued experienced a relapse within three years, and 
the majority of patients may require a lifelong treatment 
(24). These issues stress the need for treatment modalities 
with fewer adverse effects and higher efficacy. Based on 
our findings, we can argue that BUD/AZA treatment is 
as efficacious as PRED/AZA treatment in achieving 
taBle 3. Biochemical complete response and adverse effect rates in treatment groups
Prednisolone/azathioprine (n = 25) Budesonide/azathioprine (n = 25) P*
Biochemical complete response, n (%) 17 (68) 18 (72) 0.231
Adverse effect, n (%)  9 (36)  5 (20) 0.173
*χ2 test.
taBle 4. total adverse effects and treatment discontinuation rates among treatment groups
Prednisolone/azathioprine (n = 25) Budesonide/azathioprine (n = 25)
Total adverse effects 15 7
Acne  4 2
Hirsutism  3 1
Myopathy  1 1
Moon face  4 1
Buffalo hump  1 1
Striae  2 1
Discontinued treatment  2 0
Myopathy  1 0
Hirsutism  1 0
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an early biochemical response but that it may cause fewer 
adverse effects.
However, these results have to be viewed in light of some 
limitations. The study had a retrospective design and lim-
ited number of patients, and did not include data on long-
term response rates. In addition, no data on liver necroin-
flammatory activity and fibrosis scores at the 6th month 
were available.
This study suggests that BUD is as effective as PRED in 
achieving remission in AIH, and we expect that it may be-
come the first-line treatment of choice, especially in pa-
tients with obesity, diabetes, treatment-resistant hyperten-
sion or glaucoma owing to the lower adverse effects rates. 
Naturally, these findings should be supported by further 
prospective studies investigating liver histology.
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